MISTIE 3 in the final stretch!

The MISTIE III clinical trial, evaluating catheter-delivered thrombolysis for the treatment of intracerebral hemorrhage, is on track to complete enrollment in mid-2017.  The 400th patient, out of 500 planned, was enrolled on 01-November!

Currently, there are 62 active sites which have screened over 15,000 subjects. There were 173 patients enrolled over the trailing twelve months, for an average of 14.4 patients randomized each month, albeit there is notable month-to-month variability with enrollment generally being higher in the winter months. Extrapolating, that suggests that enrollment should complete by June, which would be two months ahead of plan. Follow-up of the last enrolling patient should be complete 12 months later.

M3 November Monthly Webinar: CLEAR IV Takeover
Save the Date: MISTIE III Quarterly Refresher

MISTIE-3 Site Locations